Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Engineered nanodendritic sonosensitizers empower sonodynamic-elicited ferroptosis and PANoptosis against platinum-resistant breast cancer.

Created on 25 Sep 2026

Authors

Jiahui Chen, Yu Shen, Yi Zheng, Jiwen Kang, Xifu Wang, Xuehong Diao, Yu Chen, Rong Wu

Published in

Materials today. Bio. Volume 41. Pages 103678. Epub Sep 16, 2026.

Abstract

Cisplatin-resistant breast cancer continues to pose a major clinical challenge, largely due to sophisticated cellular defense mechanisms that compromise the effectiveness of conventional chemotherapy. Ferroptosis and PANoptosis, as programmed cell death pathways, have emerged as promising strategies to circumvent treatment resistance. In this study, Pt56Mn44 nanodendrites have been designed and engineered as high-performance ultrasound-activatable sonosensitizers for efficient sonodynamic therapy of cisplatin-resistant breast cancer. The nanodendrites feature a narrow bandgap structure that facilitates enhanced electron-hole separation under ultrasound irradiation, leading to highly efficient reactive oxygen species (ROS) generation. Importantly, the resulting nanodendrites effectively suppressed the growth of cisplatin-resistant breast tumors through a coordinated multi-mechanistic action. The released Pt(II) ions induced DNA damage and promoted apoptosis while evading common resistance pathways. Concurrently, Mn(II) ions depleted intracellular glutathione and downregulated glutathione peroxidase 4, precipitating ferroptotic cell death. The sonodynamic effect further disrupted mitochondrial integrity, elevated ROS levels, and activated PANoptosis. A synergistic interaction between metal ion-mediated effects and sonodynamic radical oxidation enabled simultaneous induction of multiple cell death programs, collectively overcoming cisplatin resistance of cancer cells. The engineered nanodendrites also exhibited favorable biocompatibility, supporting their high potential as a translatable therapeutic strategy for cisplatin-resistant breast cancer and other treatment-refractory malignancies.

PMID:
42787986
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement